PRTA

PRTA's headline numbers look catastrophic — FY2025 revenue collapsed 92.8% to $9.68M, net loss ballooned to $244M, ROE is -87% and the P/S of 53.9 is meaningless — but the filing reframes the story. Revenue here is lumpy collaboration/milestone income, not a product business; the 2021 peak of $201M and the subsequent whipsaw down to ~$10M reflect one-time milestones (including the Novo Nordisk purchase of the ATTR/coramitug business), not an eroding franchise. The right lens is a late-stage clinical biotech whose most expensive programs are now other companies' problem: prasinezumab (Parkinson's) is Roche-partnered, BMS-986446/PRX005 (Alzheimer's tau) and PRX019 are licensed to Bristol Myers Squibb, and Novo owes contingent milestones on ATTR. Prothena keeps economic upside on these shots while shedding most of the trial cost.

The balance sheet backs a wait-and-see stance rather than a solvency worry. Cash is $308M against total liabilities of just $46.3M (liabilities/equity 0.17x) and no meaningful debt. Critically, MD&A guides FY2026 net cash used in operating and investing to only $50-55M — a dramatic cut from the -$164M FY2025 operating cash burn, driven by the $13.3M restructuring plan. That implies roughly 5+ years of self-funded runway before dilution becomes forced, an unusually comfortable position for a name trading near lows. Backing out $308M cash from the $522M market cap leaves an enterprise value near $214M for a partnered Parkinson's/Alzheimer's/rare-amyloid portfolio plus milestone streams — not obviously expensive.